Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors

Pfizer Inc. (NYSE:PFE) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Pfizer Inc. (NYSE:PFE) reported positive topline results from its Phase 3 BASIS study, which evaluated HYMPAVZI™ (marstacimab) in patients with hemophilia A or B with inhibitors.

The annualized bleeding rate was reduced by 93% with once-weekly subcutaneous medication as opposed to on-demand intravenous treatment (1.39 vs. 19.78; p < 0.0001). Furthermore, HYMPAVZI was superior in all secondary endpoints linked to bleeding and was usually well-tolerated; no thromboembolic events or fatalities were observed.

HYMPAVZI was investigated in 48 patients over 12 months, with a focus on a high-need population: 20% of hemophilia A and 3% of hemophilia B patients develop inhibitors that negate traditional factor replacement therapy. Pfizer Inc. (NYSE:PFE) developed the treatment, which functions by blocking the tissue factor pathway inhibitor instead of substituting FVIII or FIX. HYMPAVZI, which is administered using a pre-filled pen, provides patients with few other options with a straightforward preventative approach. Pfizer Inc. (NYSE:PFE) will begin regulatory filings after conducting a thorough data review. It is among the Best Weight Loss Stocks.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.